Physician profile
Mary E Ogden
NPI 1043392715
$1,355.18
in general payments reported to CMS, 2019-2025
21 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $222 · 2023: $203 · 2024: $395 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.57 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $344.60 | 2021-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $224.99 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $113.23 | 2022-2024 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $104.47 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $102.81 | 2021-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $88.18 | 2022-2024 | Lupkynis |
| Amgen INC. | $63.80 | 2021-2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $46.89 | 2021-2024 | Farxiga |
| Glaxosmithkline, LLC. | $30.85 | 2021-2023 | Benlysta |
| Kyowa Kirin, INC. | $29.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $26.92 | 2025 | |
| Opko Pharmaceuticals, LLC | $21.95 | 2021 | |
| Calliditas Therapeutics US INC. | $21.77 | 2025 | Tarpeyo |
| Genzyme Corporation | $20.95 | 2024 | |
| Daiichi Sankyo INC. | $20.34 | 2024 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $19.10 | 2025 | Empaveli |
| Xeris Pharmaceuticals, INC. | $18.38 | 2025 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2022 | |
| Horizon Therapeutics Plc | $13.82 | 2023 | Krystexxa |
| Shield Therapeutics INC | $13.29 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.